This suggests that this family of kinases, particularly Lyn due to its enrichment in immune cells [41 –43 ], may be attractive targets for novel anti-inflammatory drug development in AD. In this study, we characterize the ability of four novel Src family kinase inhibitors to attenuate microgliosis in vitro.